Noah Berkowitz, M.D., Ph.D., serves as the Chief Medical Officer at Arvinas, Inc., a position he has held since joining the company in 2020. Dr. Berkowitz is a highly accomplished physician-scientist with a robust background in oncology and hematology. He earned his M.D. and Ph.D. from the University of Pennsylvania, where he also completed his residency in internal medicine and fellowship in medical oncology. His academic journey laid a strong foundation for his subsequent career in clinical research and drug development. Prior to his role at Arvinas, Dr. Berkowitz held several key positions at major pharmaceutical companies. He spent over a decade at Bristol Myers Squibb, where he was instrumental in the development of multiple oncology drugs, including Opdivo (nivolumab) and Yervoy (ipilimumab). His leadership and strategic vision were pivotal in advancing these therapies through clinical trials to regulatory approval, significantly impacting the treatment landscape for various cancers. Additionally, Dr. Berkowitz has contributed to the scientific community through numerous publications and presentations at international conferences, showcasing his commitment to advancing medical knowledge. As Chief Medical Officer at Arvinas, Dr. Berkowitz oversees the clinical development of the company's innovative protein degradation therapies. His role involves guiding the clinical strategy and execution of trials aimed at treating a range of diseases, with a particular focus on oncology. Under his leadership, Arvinas has made significant strides in developing its pipeline of novel therapeutics, leveraging the company's proprietary PROTAC technology. Dr. Berkowitz's expertise and dedication continue to drive Arvinas towards its mission of transforming the treatment of serious diseases through targeted protein degradation.